Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Appointed director

Apexigen, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/25/2023 4 Zabrowksi Dan (Director) has filed a Form 4 on Apexigen, Inc.
Txns: Disposed/sold 100,000 options to buy @ $2.65, valued at $265k
08/25/2023 4 Wertheimer Samuel P (Director) has filed a Form 4 on Apexigen, Inc.
Txns: Disposed/sold 146,383 shares @ $0
Disposed/sold 100,000 options to buy @ $2.65, valued at $265k
Disposed/sold 12,383 warrants @ $11.5, valued at $142.4k
Disposed/sold 1,845 warrants @ $1.75, valued at $3.2k
08/25/2023 4 Smith Scott Andrew (Director) has filed a Form 4 on Apexigen, Inc.
Txns: Disposed/sold 34,084 options to buy @ $6.94, valued at $236.5k
Disposed/sold 100,000 options to buy @ $2.65, valued at $265k
08/25/2023 4 RINGOLD GORDON (Director) has filed a Form 4 on Apexigen, Inc.
Txns: Disposed/sold 10,000 shares @ $0
Disposed/sold 34,084 options to buy @ $4.59, valued at $156.4k
Disposed/sold 100,000 options to buy @ $2.65, valued at $265k
Disposed/sold 5,000 warrants @ $11.5, valued at $57.5k
08/25/2023 4 Chhabra Meenu (Director) has filed a Form 4 on Apexigen, Inc.
Txns: Disposed/sold 100,000 options to buy @ $2.65, valued at $265k
08/25/2023 4 Dupont Jakob (Director) has filed a Form 4 on Apexigen, Inc.
Txns: Disposed/sold 34,084 options to buy @ $4.59, valued at $156.4k
Disposed/sold 20,489 options to buy @ $0
Disposed/sold 100,000 options to buy @ $2.65, valued at $265k
08/25/2023 4 CROSS HERB (Director) has filed a Form 4 on Apexigen, Inc.
Txns: Disposed/sold 34,084 options to buy @ $6.94, valued at $236.5k
Disposed/sold 100,000 options to buy @ $2.65, valued at $265k
08/25/2023 4 Wong Amy (SVP, Finance and Operations) has filed a Form 4 on Apexigen, Inc.
Txns: Paid exercise price by delivering 15,561 shares @ $0.3851, valued at $6k
Disposed/sold 66,565 shares @ $0
Disposed/sold 22,333 options to buy @ $1.27, valued at $28.4k
Disposed/sold 8,708 options to buy @ $1.47, valued at $12.8k
Disposed/sold 230,507 options to buy @ $1.66, valued at $382.6k
Disposed/sold 15,367 options to buy @ $2.25, valued at $34.6k
Disposed/sold 13,830 options to buy @ $2.25, valued at $31.1k
Disposed/sold 71,159 options to buy @ $3.62, valued at $257.6k
Disposed/sold 28,685 options to buy @ $4.59, valued at $131.7k
Disposed/sold 25,611 options to buy @ $4.59, valued at $117.6k
Disposed/sold 15,366 options to buy @ $4.59, valued at $70.5k
08/25/2023 4 Sarena Francis Willard (President and COO) has filed a Form 4 on Apexigen, Inc.
Txns: Paid exercise price by delivering 31,123 shares @ $0.3851, valued at $12k
Disposed/sold 124,296 shares @ $0
Disposed/sold 269,847 options to buy @ $4.79, valued at $1.3M
08/25/2023 4 Hsu Frank J. (Chief Medical Officer) has filed a Form 4 on Apexigen, Inc.
Txns: Disposed/sold 16,354 shares @ $0
Disposed/sold 224,872 options to buy @ $4.79, valued at $1.1M
Disposed/sold 27,000 options to buy @ $2.46, valued at $66.4k
08/25/2023 4 Duke William E. (CFO) has filed a Form 4 on Apexigen, Inc.
Txns: Paid exercise price by delivering 26,416 shares @ $0.3851, valued at $10.2k
Disposed/sold 128,001 shares @ $0
Disposed/sold 269,848 options to buy @ $2.46, valued at $663.8k
08/25/2023 4 Yang Xiaodong (CEO) has filed a Form 4 on Apexigen, Inc.
Txns: Granted 400,000 shares @ $0
Paid exercise price by delivering 69,161 shares @ $0.3851, valued at $26.6k
Disposed/sold 863,729 shares @ $0
Disposed/sold 219,950 options to buy @ $1.27, valued at $279.3k
Disposed/sold 20,489 options to buy @ $1.47, valued at $30.1k
Disposed/sold 461,015 options to buy @ $1.66, valued at $765.3k
Disposed/sold 35,856 options to buy @ $2.25, valued at $80.7k
Disposed/sold 30,734 options to buy @ $2.25, valued at $69.2k
Disposed/sold 295,978 options to buy @ $3.62, valued at $1.1M
Disposed/sold 99,373 options to buy @ $6.54, valued at $649.9k
Disposed/sold 12,296 options to buy @ $7.03, valued at $86.4k
08/24/2023 3/A Dupont Jakob (Director) has filed a Form 3/A on Apexigen, Inc.
08/23/2023 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
08/23/2023 8-K Appointed a new director
Docs: "THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATIONOF",
"BYLAWS OFPYXIS ONCOLOGY ACQUISITION CORP., A DELAWARE CORPORATION BYLAWS OFPYXIS ONCOLOGY ACQUISITION CORP. ARTICLE I"
08/23/2023 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
08/22/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
08/18/2023 8-K Quarterly results
08/16/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
08/15/2023 8-K Other Events  Interactive Data
08/11/2023 425 Form 425 - Prospectuses and communications, business combinations:
08/11/2023 425 Form 425 - Prospectuses and communications, business combinations:
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
06/30/2023 425 Form 425 - Prospectuses and communications, business combinations:
06/30/2023 DEFM14A Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
05/25/2023 4 Wong Amy (SVP, Finance and Operations) has filed a Form 4 on Apexigen, Inc.
Txns: Granted 75,000 shares @ $0
Paid exercise price by delivering 12,234 shares @ $0.4, valued at $4.9k
05/25/2023 4 Duke William E. (CFO) has filed a Form 4 on Apexigen, Inc.
Txns: Granted 150,000 shares @ $0
Paid exercise price by delivering 17,261 shares @ $0.4, valued at $6.9k
05/25/2023 4 Sarena Francis Willard (President and COO) has filed a Form 4 on Apexigen, Inc.
Txns: Granted 150,000 shares @ $0
Paid exercise price by delivering 20,748 shares @ $0.4, valued at $8.3k
05/25/2023 425 Form 425 - Prospectuses and communications, business combinations:
05/24/2023 425 Form 425 - Prospectuses and communications, business combinations:
05/24/2023 425 Form 425 - Prospectuses and communications, business combinations:
05/24/2023 425 Form 425 - Prospectuses and communications, business combinations:
05/24/2023 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Agreement and Plan of Merger, by and among Pyxis Oncology, Inc., Ascent Merger Sub Corp. and Apexigen, Inc",
"Form of Voting Agreement",
"Pyxis Oncology to Acquire Apexigen"
05/23/2023 4 Wertheimer Samuel P (Director) has filed a Form 4 on Apexigen, Inc.
Txns: Acquired 146,383 shares @ $0
Acquired 12,383 warrants @ $11.5, valued at $142.4k
Acquired 1,845 warrants @ $1.75, valued at $3.2k
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy